Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas

NCT03188328 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped low recruitment rate

Conditions

Inoperable Solid Tumors or Lymphomas

Interventions

DRUG: AvidinOX
DRUG: 177Lu-ST2210
DRUG: 177Lu-ST2210

Sponsor

Alfasigma S.p.A.